MedTrace Logo

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

NCT03645863 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2026-04-06

Study results available
· View outcomes & findings →

Summary

The objectives of this study are to investigate the pharmacokinetics and safety of MT-6548 co-administered with iron supplements in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

MT-6548

Oral tablet

DRUG

Iron supplement A

Oral tablet

DRUG

Iron supplement B

Oral tablet

DRUG

Iron supplement C

Oral tablet

DRUG

Iron supplement D

Oral tablet

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-27
Primary Completion
2018-09-30
Completion
2018-09-30
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03645863 on ClinicalTrials.gov